Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00126412 · ClinicalTrials.gov registry record · Phase 3
Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma
A Phase 3 study, sponsored by GE Healthcare.
- Completed
- Registry status
- Phase 3
- Development phase
- 251
- Enrollment target
NCT00126412 is a Phase 3 study that has completed, run by GE Healthcare. The registered enrollment target is 251 participants.
The verdict
NCT00126412, a Phase 3 study, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 251 participants
- Enrollment target
Study Summary
The study is designed to study the effectiveness of 123I-mIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroblastoma or phaeochromocytoma.
Interventions
- DRUG 123I-mIBG (meta-iodobenzylguanidine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251 participants |
| Start Date | 2005-08-02 |
| Est. Completion | 2006-09-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00126412
The ClinicalTrials.gov registry entry for NCT00126412 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 251 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 123I-mIBG (meta-iodobenzylguanidine) is the first listed.
NCT00126412 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00126412 about?
NCT00126412 is a clinical study titled "Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma". The study is designed to study the effectiveness of 123I-mIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroblastoma or phaeochromocytoma.
What is the current status of trial NCT00126412?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 251 participants. The study started on 2005-08-02. Estimated completion is 2006-09-27.
What interventions are being tested in trial NCT00126412?
The interventions under investigation include: 123I-mIBG (meta-iodobenzylguanidine) (DRUG).
Who is sponsoring clinical trial NCT00126412?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.